CIK 0001398733 · Non-accelerated filer<br>Smaller reporting company
Aquestive Therapeutics, Inc.
Sign in to watch- Ticker
- AQST
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 208623253
- Phone
- 908-941-1900
- Business address
- 184 LIBERTY CORNER ROAD, SUITE 305, WARREN, NJ
- Former names
- MonoSol Rx, Inc.
- Open-market buys, last 90 days
- $99,331
- in 1 filing
- Open-market sales, last 90 days
- $378,930
- in 4 filings, $379K under 10b5-1 plans
Net −$279,599. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-09-04 | Jung Cassie Chief Operating Officer | Option exercise 10b5-1 | +25,000 | $0.71 | $18K | 345,526 |
| 2025-09-04 | Jung Cassie Chief Operating Officer | Sale 10b5-1 | −62,180 | $5.00 | $311K | 283,346 |
| 2025-09-04 | Jung Cassie Chief Operating Officer | Option exercise · Non-Qualified Stock Option (right to buy) 10b5-1 | −25,000 | 0 | ||
| 2025-09-04 | Jung Cassie Chief Operating Officer | Option exercise · Non-Qualified Stock Option (right to buy) 10b5-1 | −25,000 | 0 | ||
| 2025-08-14 | Korczynski Sherry Chief Commercial Officer | Grant or award | +25,000 | 181,858 | ||
| 2025-08-09 | Kraus Carl N Chief Medical Officer | Shares withheld for taxes | −10,819 | $3.90 | $42K | 302,747 |
| 2025-06-11 | BROWN GREGORY B Director | Grant or award · Stock Option (Right to Purchase) | +42,000 | $3.41 | $143K | 42,000 |
| 2025-06-11 | Krop Julie Director | Grant or award · Stock Option (Right to Purchase) | +42,000 | $3.41 | $143K | 42,000 |
| 2025-06-11 | MORRIS TIMOTHY E Director | Grant or award · Stock Option (right to purchase) | +42,000 | $3.41 | $143K | 42,000 |
| 2025-06-11 | Jenkins Abigail L. Director | Grant or award · Non-Qualified Stock Option (right to buy) | −42,000 | $3.41 | $143K | 42,000 |
| 2025-06-11 | Cochran John Director | Grant or award · Stock Option (Right to Purchase) | +42,000 | $3.41 | $143K | 42,000 |
| 2025-06-11 | Taglietti Marco Director | Grant or award · Stock Option (Right to Purchase) | +42,000 | $3.41 | $143K | 42,000 |
| 2025-06-09 | Korczynski Sherry SVP Sales and Marketing | Shares withheld for taxes | −2,714 | $3.54 | $10K | 156,858 |
| 2025-05-15 | Cioffi Melina SVP, Regulatory Affairs | Grant or award | +20,000 | 202,261 | ||
| 2025-03-10 | Wargacki Stephen Chief Science Officer | Shares withheld for taxes | −4,572 | $2.54 | $12K | 343,552 |
| 2025-03-10 | Jung Cassie Chief Operating Officer | Shares withheld for taxes | −2,182 | $2.54 | $6K | 295,526 |
| 2025-03-09 | Wargacki Stephen Chief Science Officer | Shares withheld for taxes | −15,431 | $2.65 | $41K | 348,124 |
| 2025-03-09 | Jung Cassie Chief Operating Officer | Shares withheld for taxes | −7,997 | $2.65 | $21K | 297,708 |
| 2025-03-09 | TOTH A ERNEST JR Chief Financial Officer | Shares withheld for taxes | −8,736 | $2.65 | $23K | 339,366 |
| 2025-03-09 | BRAENDER LORI J Chief Legal Officer | Shares withheld for taxes | −10,658 | $2.65 | $28K | 402,981 |
Page 5 of 24 · 462 trades